search
Back to results

The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2

Primary Purpose

T2DM (Type 2 Diabetes Mellitus)

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Treatment A
Treatment B
Treatment C
Sponsored by
AJU Pharm Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for T2DM (Type 2 Diabetes Mellitus)

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Individuals whose age is over 19 and under 65 years old when visiting for initial screening test.
  2. Body mass index(BMI) between 17.5~30.5 kg/m^2 and the body weight must be over 55 kg(men) or 45 kg(women) (Body mass index (BMI) = weight (kg) / height (m)^2) .
  3. Individuals with no congenital or chronic disease in three years, no history of symptoms in internal treatment, or no knowledge in the area.
  4. Due to the special characteristics of drugs, the participators must be qualified to do the clinical screening after examined through hematology test and blood chemistry analysis, urinary test, the electrocardiogram (ECG), and etc.
  5. The participants must be volunteered and sign in an informed consent document proven by Chonbuk National University IRB before joining a study to show that he was given informed the purpose of tests and the special characteristics of drugs.
  6. Individuals who agreed proper contraception during the study
  7. The participants must have an ability and willingness to participate throughout the entire trials.

Exclusion Criteria:

  1. Individuals with a medical evidence or a history (excluding dental history of periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune disease.
  2. Individual who had a history of gastrointestinal related disease which can be affected the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's disease) or surgeries (except a simple appendectomy or herniotomy).
  3. Individual who had following results after examination(a. ALT or AST > twice higher than Upper limit of normal value).
  4. Individual Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (12%) (125 mL) = 12g).
  5. Individual whose blood pressure < 90 or ≥160(systolic blood pressure) or < 50 or ≥ 100(diastolic blood pressure).
  6. Individuals who had been administered investigational product(s) from other clinical study or bioequivalence study within 180 days prior to the first dose of this study(except when subject have not taken investigational product(s)).
  7. Individual who had a medical history of alcohol and drug abuses.
  8. Individual who had taken a drug that has a control of metabolic rate (activation or inhibition) in 30 days before the first taking of clinical testing drug.
  9. Individual who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders.
  10. A person who is not determined unsuitable to participate in this test by the researchers.

Sites / Locations

  • Min-gul Kim

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Sequence 1

Arm Description

Period 1: Treatment A(AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days) Wash-out for 7 days Period 2: Treatment B(AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days) Period 3: Treatment C(AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days)

Outcomes

Primary Outcome Measures

AUCτ of AJU-A51R1 and AJU-A51R2
Area Under Curve tau
Css,max of AJU-A51R1 and AJU-A51R2
Cmax, steady state

Secondary Outcome Measures

Full Information

First Posted
July 12, 2021
Last Updated
July 12, 2021
Sponsor
AJU Pharm Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04970940
Brief Title
The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2
Official Title
An Open-label, Multiple Dose, Crossover Study to Evaluate the Drug-drug Interaction Between AJU-A51R1 and AJU-A51R2 in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
July 2, 2020 (Actual)
Primary Completion Date
October 7, 2020 (Actual)
Study Completion Date
December 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AJU Pharm Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate a pharmacokinetic drug interaction between AJU-A51R1 and AJU-A51R2 in healthy male volunteers.
Detailed Description
This study is to investigate drug-drug interaction between AJU-A51R1 and AJU-A51R2.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
T2DM (Type 2 Diabetes Mellitus)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sequence 1
Arm Type
Experimental
Arm Description
Period 1: Treatment A(AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days) Wash-out for 7 days Period 2: Treatment B(AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days) Period 3: Treatment C(AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days)
Intervention Type
Drug
Intervention Name(s)
Treatment A
Other Intervention Name(s)
Period 1
Intervention Description
AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days
Intervention Type
Drug
Intervention Name(s)
Treatment B
Other Intervention Name(s)
Period 2
Intervention Description
AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days
Intervention Type
Drug
Intervention Name(s)
Treatment C
Other Intervention Name(s)
Period 3
Intervention Description
AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days
Primary Outcome Measure Information:
Title
AUCτ of AJU-A51R1 and AJU-A51R2
Description
Area Under Curve tau
Time Frame
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours post-dose
Title
Css,max of AJU-A51R1 and AJU-A51R2
Description
Cmax, steady state
Time Frame
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours post-dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Individuals whose age is over 19 and under 65 years old when visiting for initial screening test. Body mass index(BMI) between 17.5~30.5 kg/m^2 and the body weight must be over 55 kg(men) or 45 kg(women) (Body mass index (BMI) = weight (kg) / height (m)^2) . Individuals with no congenital or chronic disease in three years, no history of symptoms in internal treatment, or no knowledge in the area. Due to the special characteristics of drugs, the participators must be qualified to do the clinical screening after examined through hematology test and blood chemistry analysis, urinary test, the electrocardiogram (ECG), and etc. The participants must be volunteered and sign in an informed consent document proven by Chonbuk National University IRB before joining a study to show that he was given informed the purpose of tests and the special characteristics of drugs. Individuals who agreed proper contraception during the study The participants must have an ability and willingness to participate throughout the entire trials. Exclusion Criteria: Individuals with a medical evidence or a history (excluding dental history of periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune disease. Individual who had a history of gastrointestinal related disease which can be affected the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's disease) or surgeries (except a simple appendectomy or herniotomy). Individual who had following results after examination(a. ALT or AST > twice higher than Upper limit of normal value). Individual Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (12%) (125 mL) = 12g). Individual whose blood pressure < 90 or ≥160(systolic blood pressure) or < 50 or ≥ 100(diastolic blood pressure). Individuals who had been administered investigational product(s) from other clinical study or bioequivalence study within 180 days prior to the first dose of this study(except when subject have not taken investigational product(s)). Individual who had a medical history of alcohol and drug abuses. Individual who had taken a drug that has a control of metabolic rate (activation or inhibition) in 30 days before the first taking of clinical testing drug. Individual who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders. A person who is not determined unsuitable to participate in this test by the researchers.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Min-gul Kim
Organizational Affiliation
Jeonbuk University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Min-gul Kim
City
Jeonju
State/Province
Korea
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2

We'll reach out to this number within 24 hrs